D.A. Davidson & Co. Biocryst Pharmaceuticals Inc Transaction History
D.A. Davidson & Co.
- $15.1 Billion
- Q3 2025
Shares
2 transactions
Others Institutions Holding BCRX
# of Institutions
312Shares Held
200MCall Options Held
640KPut Options Held
507K-
Vanguard Group Inc Valley Forge, PA21.8MShares$154 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$141 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY12.2MShares$86.2 Million1.72% of portfolio
-
State Street Corp Boston, MA9.81MShares$69.4 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.39MShares$66.5 Million6.02% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.32B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...